JPMorgan Chase & Co. Lowers Abcam (LON:ABC) Price Target to GBX 1,134

Abcam (LON:ABC) had its price target lowered by JPMorgan Chase & Co. from GBX 1,144 ($14.95) to GBX 1,134 ($14.82) in a report published on Monday morning, ThisIsMoney.Co.Uk reports. JPMorgan Chase & Co. currently has a neutral rating on the stock.

ABC has been the topic of several other research reports. Berenberg Bank reiterated a buy rating and set a GBX 1,330 ($17.38) price target on shares of Abcam in a report on Monday, September 9th. Peel Hunt reiterated an add rating and set a GBX 1,300 ($16.99) price target (down previously from GBX 1,430 ($18.69)) on shares of Abcam in a report on Monday, September 9th.

Shares of ABC stock opened at GBX 1,172 ($15.31) on Monday. Abcam has a 12 month low of GBX 1,006 ($13.15) and a 12 month high of GBX 1,523 ($19.90). The business’s 50 day moving average is GBX 1,199.28 and its two-hundred day moving average is GBX 1,288.14. The company has a market cap of $2.42 billion and a PE ratio of 53.76.

The business also recently disclosed a dividend, which will be paid on Friday, November 29th. Stockholders of record on Thursday, November 7th will be paid a GBX 8.58 ($0.11) dividend. This is an increase from Abcam’s previous dividend of $3.55. The ex-dividend date of this dividend is Thursday, November 7th. This represents a dividend yield of 0.74%. Abcam’s dividend payout ratio (DPR) is presently 0.55%.

In related news, insider Alan Thomas Hirzel acquired 4,250 shares of the stock in a transaction dated Tuesday, September 10th. The shares were acquired at an average price of GBX 1,139 ($14.88) per share, for a total transaction of £48,407.50 ($63,252.97). Also, insider Gavin Wood acquired 2,500 shares of the stock in a transaction dated Friday, September 13th. The stock was bought at an average price of GBX 1,157 ($15.12) per share, for a total transaction of £28,925 ($37,795.64).

Abcam Company Profile

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.

See Also: Commodities

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit